FI19991730A - Enantiomers of 1 - ((4-chlorophenylmethyl) -4 - ((4-methylphenyl) sulfonyl) piperazine - Google Patents
Enantiomers of 1 - ((4-chlorophenylmethyl) -4 - ((4-methylphenyl) sulfonyl) piperazineInfo
- Publication number
- FI19991730A FI19991730A FI991730A FI19991730A FI19991730A FI 19991730 A FI19991730 A FI 19991730A FI 991730 A FI991730 A FI 991730A FI 19991730 A FI19991730 A FI 19991730A FI 19991730 A FI19991730 A FI 19991730A
- Authority
- FI
- Finland
- Prior art keywords
- ethyl
- methylphenyl
- enantiomers
- chlorophenylmethyl
- piperazine
- Prior art date
Links
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 title abstract 3
- LGROXRPZBHHOPD-UHFFFAOYSA-N 1-[(4-chlorophenyl)methyl]-4-(4-methylphenyl)sulfonylpiperazine Chemical compound C1=CC(C)=CC=C1S(=O)(=O)N1CCN(CC=2C=CC(Cl)=CC=2)CC1 LGROXRPZBHHOPD-UHFFFAOYSA-N 0.000 title 1
- -1 (3-methylphenyl)methyl Chemical group 0.000 abstract 7
- HIKIBGRLBOCOAZ-UHFFFAOYSA-N 1-[[1-(4-chlorophenyl)cyclohexa-2,4-dien-1-yl]methyl]piperazine Chemical class C1=CC(Cl)=CC=C1C1(CN2CCNCC2)C=CC=CC1 HIKIBGRLBOCOAZ-UHFFFAOYSA-N 0.000 abstract 2
- 206010020751 Hypersensitivity Diseases 0.000 abstract 2
- 230000007815 allergy Effects 0.000 abstract 2
- 229940079593 drug Drugs 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/06—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by halogen atoms or nitro radicals
- C07D295/073—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by halogen atoms or nitro radicals with the ring nitrogen atoms and the substituents separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
- C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/22—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
- C07D295/26—Sulfur atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Anesthesiology (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Hydrogenated Pyridines (AREA)
Abstract
The use of levorotatory or dextrorotatory enantiomers of 1-(4-chlorophenyl)phenylmethylpiperazine derivatives (V) or their salts in medicines for the treatment of allergies, is new. The use of levorotatory or dextrorotatory enantiomers of 1-(4-chlorophenyl)phenylmethylpiperazine derivatives of formula (V) or their salts, in medicines for the treatment of allergies, is new: R = H, (3-methylphenyl)methyl, (4-tert-butylphenyl)methyl, 2-(2-hydroxyethoxy)ethyl, 2-(2-(hydroxyethoxy)ethoxy)ethyl, 2-(carbamoylethoxy)ethyl, 2-(methoxycarbonylmethoxy)ethyl or 2-(carboxymethoxy)ethyl.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB9305282 | 1993-03-15 | ||
GB939305282A GB9305282D0 (en) | 1993-03-15 | 1993-03-15 | Enantiomers of 1-(4-chlorophenyl)phenylmethyl)-4-(4-methylphenyl)sulphonyl)piperazine |
Publications (2)
Publication Number | Publication Date |
---|---|
FI19991730A true FI19991730A (en) | 1999-08-16 |
FI105915B FI105915B (en) | 2000-10-31 |
Family
ID=10732080
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
FI941134A FI105477B (en) | 1993-03-15 | 1994-03-10 | Enantiomers of 1 - [(4-chlorophenyl) phenylmethyl] -4 - [(4-methylphenyl) sulfonyl] piperazine and process for their preparation |
FI991730A FI105915B (en) | 1993-03-15 | 1999-08-16 | The process prepares enantiomers of 1 - [(4-chlorophenyl) phenylmethyl] -piperazine |
FI991729A FI105914B (en) | 1993-03-15 | 1999-08-16 | The process for the preparation of a pharmaceutically active enantiomer of 1 - [(4-chlorophenyl) phenylmethyl] -4 - [(4-methylphenyl) sulfonyl] piperazine |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
FI941134A FI105477B (en) | 1993-03-15 | 1994-03-10 | Enantiomers of 1 - [(4-chlorophenyl) phenylmethyl] -4 - [(4-methylphenyl) sulfonyl] piperazine and process for their preparation |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
FI991729A FI105914B (en) | 1993-03-15 | 1999-08-16 | The process for the preparation of a pharmaceutically active enantiomer of 1 - [(4-chlorophenyl) phenylmethyl] -4 - [(4-methylphenyl) sulfonyl] piperazine |
Country Status (24)
Country | Link |
---|---|
US (17) | US5478941A (en) |
EP (3) | EP1413307A1 (en) |
JP (3) | JP3267434B2 (en) |
KR (1) | KR100322415B1 (en) |
AT (2) | ATE267185T1 (en) |
AU (1) | AU678426B2 (en) |
CA (2) | CA2118859C (en) |
DE (2) | DE69424893T2 (en) |
DK (1) | DK0617028T3 (en) |
ES (2) | ES2221262T3 (en) |
FI (3) | FI105477B (en) |
GB (1) | GB9305282D0 (en) |
GR (1) | GR3034340T3 (en) |
HK (1) | HK1024232A1 (en) |
HU (1) | HU219230B (en) |
NO (2) | NO305908B1 (en) |
NZ (1) | NZ260062A (en) |
PL (1) | PL178546B1 (en) |
PT (1) | PT617028E (en) |
RU (1) | RU2118320C1 (en) |
SG (1) | SG43683A1 (en) |
SI (2) | SI0955295T1 (en) |
TW (1) | TW237452B (en) |
ZA (1) | ZA941724B (en) |
Families Citing this family (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5831066A (en) | 1988-12-22 | 1998-11-03 | The Trustees Of The University Of Pennsylvania | Regulation of bcl-2 gene expression |
ATE177636T1 (en) * | 1992-09-24 | 1999-04-15 | Sepracor Inc | TRANSDERMAL TREATMENT OF HURTS WITH OPTICALLY PURE (+)-CETIRIZINE |
WO1994006429A1 (en) * | 1992-09-24 | 1994-03-31 | Sepracor, Inc. | Compositions for treating allergic disorders using (-) cetirizine |
GB9305282D0 (en) * | 1993-03-15 | 1993-05-05 | Ucb Sa | Enantiomers of 1-(4-chlorophenyl)phenylmethyl)-4-(4-methylphenyl)sulphonyl)piperazine |
EP0690051B1 (en) * | 1994-01-14 | 2001-07-18 | Azwell Inc. | Diazacycloalkanealkylsulfonamide derivative |
CN1058638C (en) * | 1995-06-27 | 2000-11-22 | 中国药品生物制品检定所 | Extraction of allergen of intracellular Mycobacterium |
AU7455798A (en) | 1997-06-04 | 1998-12-21 | Nippon Shoji Kaisha, Ltd. | Process for producing piperazinesulfonamide derivatives and salts thereof |
US6384038B1 (en) | 1998-04-14 | 2002-05-07 | Sepracor Inc. | Methods and compositions using cetirizine in combination with leukotriene inhibitors or decongestants |
IL124195A (en) * | 1998-04-23 | 2000-08-31 | Chemagis Ltd | Process for the preparation of esters of 2-¬4-¬4-chlorophenyl¾phenylmethyl¾-1-piperazinyl¬ethoxy¾acetic acid |
US6432961B1 (en) * | 1998-08-18 | 2002-08-13 | Ucb S.A. | Method for preventing the onset of asthma |
WO2001040211A1 (en) * | 1999-11-30 | 2001-06-07 | EGIS Gyógyszergyár Rt. | A PROCESS FOR THE PREPARATION OF {2-[4-(α-PHENYL-p-CHLOROBENZYL)PIPERAZIN-1-YL]ETHOXY}ACETIC ACID AND NOVEL INTERMEDIATES THEREFOR |
JP2002249487A (en) | 2001-02-22 | 2002-09-06 | Sumitomo Chem Co Ltd | 4-(tert-butoxycarbonyl)piperazine derivative, optically active acid addition salt of the same, method for producing them and optically active 1-[(substituted phenyl)phenylmethylpiperazine which uses them |
US6977301B1 (en) | 2001-05-29 | 2005-12-20 | Ucb, S.A. | Process for preparing (S) and (R)—2-[4-(4-chlorobenzhydryl)piperazin-1-yl]-ethoxyacetamide |
US7199241B1 (en) | 2001-05-29 | 2007-04-03 | Ucb, S.A. | Process for preparing (S) and (R)-2-[4-(4-chlorobenzhydryl)piperazin-1-yl]-ethoxyacetamide |
CN1692105A (en) * | 2002-12-04 | 2005-11-02 | 雷迪实验室有限公司 | Cetirizine dihydrochloride polymorph and preparation method thereof |
EP1620127A4 (en) * | 2003-03-20 | 2007-04-04 | Rinat Neuroscience Corp | Methods for treating taxol-induced gut disorder |
US7577727B2 (en) * | 2003-06-27 | 2009-08-18 | Newisys, Inc. | Dynamic multiple cluster system reconfiguration |
KR100503443B1 (en) | 2004-02-02 | 2005-07-22 | 한림제약(주) | Processes for preparing an optically active cetirizine or its salt |
EA012575B1 (en) * | 2005-03-03 | 2009-10-30 | Юсб Фархим Са | Pyroglutamate salts and their use in the optical resolution of intermediates for the synthesis of dextrocetirizine and levocetirizine |
HU227074B1 (en) * | 2005-12-08 | 2010-06-28 | Egis Gyogyszergyar Nyrt | An optically active carbamic acid derivative, method for producing the same and use as a pharmaceutical intermediate |
WO2008110586A2 (en) | 2007-03-12 | 2008-09-18 | Krka, Tovarna Zdravil, D.D., Novo Mesto | New process for the preparation of levocetirizine and intermediates thereof |
WO2008152650A1 (en) | 2007-06-15 | 2008-12-18 | Symed Labs Limited | Process for preparation of substantially optically pure levorotatory and dextrorotatory enantiomers of cetirizine using novel intermediates |
US20090062305A1 (en) * | 2007-08-29 | 2009-03-05 | Protia, Llc | Deuterium-enriched cetirizine |
US20090082364A1 (en) * | 2007-09-26 | 2009-03-26 | Protia, Llc | Deuterium-enriched levocedtirizine |
KR101427100B1 (en) | 2007-10-23 | 2014-08-08 | 주식회사 씨트리 | Method for Preparing an Optically Active 1-[(4-chlorophenyl)phenylmethyl] -piperazine |
DE602007012725D1 (en) | 2007-11-21 | 2011-04-07 | Synthon Bv | Process for the preparation of N- (diphenylmethyl) piperazines |
US7989623B2 (en) * | 2007-11-21 | 2011-08-02 | Synthon Bv | Process for making n-(diphenylmethyl)piperazines |
KR100954755B1 (en) * | 2007-12-17 | 2010-04-27 | 한미약품 주식회사 | Method for preparing r---1-[4-chloro-phenylphenyl-methyl]piperazine |
JP2011523659A (en) * | 2008-06-02 | 2011-08-18 | シプラ・リミテッド | Method for synthesizing levocetirizine and intermediate used therefor |
KR100998067B1 (en) | 2008-09-08 | 2010-12-03 | 주식회사 삼오제약 | A novel Bis1-[4-chlorophenylphenylmethyl]piperazine-2,3-Dibenzoyl tartarate intermediate salt and the method for isolating optically active 1-[4-chlorophenylphenylmethyl]piperazine using thereby |
US20100145049A1 (en) * | 2008-11-21 | 2010-06-10 | Jie Zhu | Process for making n-(diphenylmethyl)piperazines |
CN102459210B (en) * | 2009-04-22 | 2015-09-02 | 埃克希金医药品有限公司 | Arylsulfonamide ccr 3 antagonists |
CN101928223A (en) * | 2009-06-26 | 2010-12-29 | 华东理工大学 | Resolution method of (R)-(-)-4-chloro benzhydrylamine |
WO2012101475A1 (en) | 2011-01-27 | 2012-08-02 | Jubilant Life Sciences Limited | An improved process for the preparation of antihistaminic drugs via a novel carbamate intermediate |
KR101418404B1 (en) | 2012-01-06 | 2014-07-10 | 한미약품 주식회사 | Stable pharmaceutical formulation for oral administration comprising levocetirizine or a pharmaceutically acceptable salt thereof, and montelukast or a pharmaceutically acceptable salt thereof |
WO2013158318A1 (en) | 2012-04-16 | 2013-10-24 | Zemtsov Enterprises, Llc | Formulations and methods for treatment of acne and inflammatory skin conditions |
CN103613567A (en) * | 2012-11-09 | 2014-03-05 | 焦作福瑞堂制药有限公司 | Synthetic process for chlorcyclizine hydrochloride |
KR102226833B1 (en) | 2013-06-28 | 2021-03-12 | 한미약품 주식회사 | Complex granule formulation having improved stability comprising levocetirizine and montelukast |
CN104045607B (en) * | 2014-05-21 | 2016-04-13 | 丽珠医药集团股份有限公司 | A kind of purification process of cetrizine hcl |
CN111205247B (en) * | 2020-04-22 | 2020-08-14 | 湖南九典宏阳制药有限公司 | Preparation method of levocetirizine |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2899436A (en) * | 1959-08-11 | chjch | ||
BE540057A (en) * | ||||
US2709169A (en) * | 1955-05-24 | X c chs | ||
CA568380A (en) * | 1959-01-06 | Morren Henri | Ethers of piperazine and method of their preparation | |
BE523901A (en) * | ||||
GB752331A (en) * | 1948-09-30 | 1956-07-11 | Abbott Lab | Improvements in or relating to n, n-disubstituted piperazines and process of preparing the same |
US2861072A (en) * | 1952-07-19 | 1958-11-18 | Abbott Lab | Preparation of piperazine derivatives |
US2709167A (en) * | 1952-09-10 | 1955-05-24 | Geigy Ag J R | Chromium-containing monoazo dyestuffs |
US2897436A (en) * | 1954-09-29 | 1959-07-28 | Amchem Prod | Indicating and control apparatus for electrolyte concentration and the like |
US3406174A (en) * | 1964-10-23 | 1968-10-15 | Sandoz Ag | Benzylsulfamides |
DK154078C (en) * | 1981-02-06 | 1989-05-22 | Ucb Sa | METHOD OF ANALOGUE FOR THE PREPARATION OF 2- (2- (4- (DIPHENYL-METHYL) -1-PIPERAZINYL) ETHOXY) -ACETAMIDES OR ACID ADDITION SALTS. |
US4749700A (en) * | 1984-10-23 | 1988-06-07 | Nastech Pharmaceutical Co, Inc. | Novel methods of administering antihistamines, antinausea and antiemetic pharmaceutical agents and novel dosage forms containing same |
DE3640247A1 (en) * | 1986-11-25 | 1988-05-26 | Basf Ag | FUNGICIDAL CYCLOHEXYLAMINE |
US4975426A (en) * | 1987-06-08 | 1990-12-04 | Analgesic Associates | Cough/cold mixtures comprising non-sedating antihistamine drugs |
US5234957A (en) * | 1991-02-27 | 1993-08-10 | Noven Pharmaceuticals, Inc. | Compositions and methods for topical administration of pharmaceutically active agents |
JP2559463B2 (en) * | 1988-06-01 | 1996-12-04 | ダイセル化学工業株式会社 | Method for optical resolution of compound having two aromatic groups at asymmetric center |
JPH0239947A (en) * | 1988-07-29 | 1990-02-08 | Seikosha Co Ltd | Printing head |
GB8827391D0 (en) * | 1988-11-23 | 1988-12-29 | Ucb Sa | Process for preparation of 2-(2-(4-((4-chlorophenyl)phenylmethyl)-1-pipera-zinyl)ethoxy)-acetic acid & its dihydrochloride |
US4882432A (en) * | 1989-01-09 | 1989-11-21 | American Home Products Corporation | Polycyclic-carbamic acid piperazinoalkyl esters and amides |
US5087627A (en) * | 1989-03-15 | 1992-02-11 | Santen Pharmaceutical Co., Ltd. | Agent for treatment of disorders of the cerebro-neural transmission system |
SG43860A1 (en) * | 1990-09-10 | 1997-11-14 | Mitsubishi Electric Corp | Coding apparatus |
WO1994006429A1 (en) | 1992-09-24 | 1994-03-31 | Sepracor, Inc. | Compositions for treating allergic disorders using (-) cetirizine |
ATE177636T1 (en) | 1992-09-24 | 1999-04-15 | Sepracor Inc | TRANSDERMAL TREATMENT OF HURTS WITH OPTICALLY PURE (+)-CETIRIZINE |
GB9305282D0 (en) * | 1993-03-15 | 1993-05-05 | Ucb Sa | Enantiomers of 1-(4-chlorophenyl)phenylmethyl)-4-(4-methylphenyl)sulphonyl)piperazine |
-
1993
- 1993-03-15 GB GB939305282A patent/GB9305282D0/en active Pending
-
1994
- 1994-03-08 US US08/207,096 patent/US5478941A/en not_active Expired - Lifetime
- 1994-03-08 TW TW083102003A patent/TW237452B/zh active
- 1994-03-09 EP EP04002438A patent/EP1413307A1/en not_active Withdrawn
- 1994-03-09 ES ES99109564T patent/ES2221262T3/en not_active Expired - Lifetime
- 1994-03-09 SI SI9430468T patent/SI0955295T1/en unknown
- 1994-03-09 DE DE69424893T patent/DE69424893T2/en not_active Expired - Fee Related
- 1994-03-09 AT AT99109564T patent/ATE267185T1/en not_active IP Right Cessation
- 1994-03-09 SI SI9430329T patent/SI0617028T1/en unknown
- 1994-03-09 SG SG1995002010A patent/SG43683A1/en unknown
- 1994-03-09 PT PT94870043T patent/PT617028E/en unknown
- 1994-03-09 EP EP94870043A patent/EP0617028B1/en not_active Expired - Lifetime
- 1994-03-09 AT AT94870043T patent/ATE193889T1/en not_active IP Right Cessation
- 1994-03-09 ES ES94870043T patent/ES2147569T3/en not_active Expired - Lifetime
- 1994-03-09 DK DK94870043T patent/DK0617028T3/en active
- 1994-03-09 DE DE69433802T patent/DE69433802T2/en not_active Expired - Fee Related
- 1994-03-09 EP EP99109564A patent/EP0955295B1/en not_active Expired - Lifetime
- 1994-03-10 NZ NZ260062A patent/NZ260062A/en not_active IP Right Cessation
- 1994-03-10 FI FI941134A patent/FI105477B/en active
- 1994-03-11 AU AU57771/94A patent/AU678426B2/en not_active Ceased
- 1994-03-11 PL PL94302565A patent/PL178546B1/en not_active IP Right Cessation
- 1994-03-11 CA CA002118859A patent/CA2118859C/en not_active Expired - Fee Related
- 1994-03-11 ZA ZA941724A patent/ZA941724B/en unknown
- 1994-03-11 CA CA002443216A patent/CA2443216C/en not_active Expired - Fee Related
- 1994-03-11 HU HU9400727A patent/HU219230B/en not_active IP Right Cessation
- 1994-03-11 NO NO940881A patent/NO305908B1/en not_active IP Right Cessation
- 1994-03-14 KR KR1019940005172A patent/KR100322415B1/en not_active IP Right Cessation
- 1994-03-14 JP JP04254794A patent/JP3267434B2/en not_active Expired - Fee Related
- 1994-03-14 RU RU94008618A patent/RU2118320C1/en active
-
1995
- 1995-06-05 US US08/460,844 patent/US5703082A/en not_active Expired - Fee Related
-
1997
- 1997-10-09 US US08/947,859 patent/US5792770A/en not_active Expired - Fee Related
-
1999
- 1999-01-26 NO NO990351A patent/NO306616B1/en not_active IP Right Cessation
- 1999-07-19 US US09/356,865 patent/US6436942B1/en not_active Expired - Fee Related
- 1999-08-16 FI FI991730A patent/FI105915B/en active
- 1999-08-16 FI FI991729A patent/FI105914B/en active
-
2000
- 2000-05-02 HK HK00102635A patent/HK1024232A1/en not_active IP Right Cessation
- 2000-09-06 GR GR20000402028T patent/GR3034340T3/en not_active IP Right Cessation
-
2001
- 2001-11-22 JP JP2001356849A patent/JP3880842B2/en not_active Expired - Fee Related
-
2002
- 2002-05-10 US US10/141,933 patent/US20030105112A1/en not_active Abandoned
- 2002-06-06 US US10/162,576 patent/US20030105113A1/en not_active Abandoned
-
2003
- 2003-03-12 US US10/385,522 patent/US20030204089A1/en not_active Abandoned
- 2003-10-07 US US10/679,376 patent/US20040072845A1/en not_active Abandoned
- 2003-12-02 US US10/724,640 patent/US20040122021A1/en not_active Abandoned
- 2003-12-02 US US10/724,611 patent/US20040122023A1/en not_active Abandoned
-
2005
- 2005-04-15 US US11/106,456 patent/US20050182070A1/en not_active Abandoned
- 2005-04-15 US US11/106,613 patent/US20050176732A1/en not_active Abandoned
- 2005-04-15 US US11/106,528 patent/US20050182069A1/en not_active Abandoned
-
2006
- 2006-06-16 US US11/453,987 patent/US20060229319A1/en not_active Abandoned
- 2006-06-16 US US11/453,986 patent/US20060229320A1/en not_active Abandoned
- 2006-07-17 US US11/487,331 patent/US20060252934A1/en not_active Abandoned
- 2006-09-29 JP JP2006266195A patent/JP2006342190A/en not_active Abandoned
-
2007
- 2007-01-11 US US11/652,092 patent/US20070142400A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
FI19991730A (en) | Enantiomers of 1 - ((4-chlorophenylmethyl) -4 - ((4-methylphenyl) sulfonyl) piperazine | |
AR016351A1 (en) | BETA CRYSTAL FORM OF THE METANSULPHONIC ACID ADDITION SALT OF 4- (4-METHYLPIPERAZIN-1-ILMETIL) -N- [4-METHYL-3- (4-PIRIDIN-3-IL) PIRIMIDIN-2-ILAMINO) PHENYL] BENZAMIDE, PHARMACEUTICAL COMPOSITION, USE OF CRYSTAL FORM FOR THE PREPARATION OF A PHARMACOLOGICAL AGENT, AND PROCESSES FOR PREPARATION | |
FI935851A0 (en) | Antiallergic moss treatment For ophthalmic or nasal Bruk | |
BR9205811A (en) | Heterocyclic derivatives of cyclic amines | |
CO5271691A1 (en) | NEW COMPOUNDS | |
ATE116312T1 (en) | ANTIMIGRAINE ALKOXYPYRIMIDINE DERIVATIVES. | |
KR950031062A (en) | Eye drops for eye drops | |
ATE117208T1 (en) | TREATMENT OF INTRAOCULAR PRESSURE WITH AN OPHTHALMIC SYNERGISTIC COMBINATION. | |
DK591488D0 (en) | 1-ACYL-3-OE4- (2-PYRIMIDINYL) -1-PIPERAZINYLAAPROPAN COMPOUNDS, THEIR USE FOR THE PREPARATION OF AN ANTI-ANXICATIVE MEDICINE AND PHARMACEUTICAL PREPARATIONS CONTAINING THESE | |
HK1054198A1 (en) | Novel use of (R)-(-)-2-Ä5-(4-fluorophenyl)-3-pyridylmethylaminomethylÜ-chromane and its physiologically acceptable salts. | |
DE3778642D1 (en) | THERAPEUTIC FOR TREATMENT OF STOMACH. | |
RO95572A2 (en) | PROCESS FOR THE PREPARATION OF 1,3-OXAZOOLIDIN -2-ONE DERIVATIVES |